Ant International Launches Alipay+ Voyager, a Built-in End-to-End AI Travel Companion for Digital Wallet and Super App Users
2.7.2025 09:12:00 EEST | Business Wire | Press release
With launch partners including Agoda, Fliggy and Trip.com, Ant International introduces Alipay+ Voyager, an AI travel companion integrated into digital wallets for the travel industry to simplify and enhance travel experiences for global consumers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250701160496/en/
A sample user interface of Alipay+ Voyager, which users can access via digital wallets
Alipay+ Voyager combines Ant International's agentic AI capabilities with the galaxy of cross-border travel services offered by OTA partners and 100 million global merchants in Alipay+'s partner ecosystem.
Through its one single AI interface embedded in e-wallets and super apps, Alipay+ Voyager assists travellers, via text or voice in their local language, to complete itinerary planning, booking, and purchasing in-destination merchant offerings with a seamless flow.
Alipay+ Voyager is first launched on three of Asia’s biggest mobile wallets, Alipay (Chinese mainland), AlipayHK (Hong Kong SAR, China) and GCash (the Philippines) ahead of the summer travel peak. It will roll out to more Alipay+ payment partners throughout 2025.
Alipay+, started as a cross-border payment technology solution, now helping 36 leading e-wallets and payment apps with 1.7 billion consumer accounts connect to over 100 million merchants. The Alipay+ Wallet Tech team has been working with e-wallet partners in emerging markets to develop payment, security and growth capabilities and solutions since 2015. Today, the team plans to further build out other agentic AI suites for different industries on Alipay+ GenAI Cockpit, its main AI platform for fintechs.
Driving Global Connectivity and Growth in the Merchant-Wallet-Consumer Ecosystem
The online travel market is expected to grow 10% annually through 2032, with mobile already making up two-thirds of traffic1. Travellers, especially Gen Zs, increasingly favour unique, hyperlocal experiences, using mobile-first, all-in-one solutions to uncover their best options.
Alipay+ Voyager has a number of distinct features:
- Intelligent end-to-end assistance from one single hub in familiar wallets: research, decision and action support before, during and after the trip;
- Real-time global-to-local connections: seamless transitioning to local services like ride-hailing, public transport, shopping, dining and sightseeing;
- Purposeful, forward-looking curation: Voyager AI intuitively understands a user’s preferences, proactively solves problems when there are issues such as flight delays or bad weather, and surfaces hyper-relevant options in real-time before a traveller even asks, all within their home e-wallet;
- A new growth gateway for merchants and OTAs: captures multiple core markets through one easy deployment across the largest regional and global e-wallets.
“Travellers today are using more tech to enhance their trips, and there is a need for the industry to adapt and meet these new and emerging expectations,” said Douglas Feagin, President of Ant International. “By integrating a proactive, always-on AI travel companion within digital wallets that consumers already use frequently, we’re empowering travel and wallet partners with new opportunities to engage travellers in a more relevant, personalised way, through every step of their journey.”
Gil Hazan, Senior Vice President of Strategic Partnerships, Agoda, said: “At Agoda, we are committed to making travel more accessible and seamless for everyone. By integrating our extensive supply network as one of Asia's leading online travel platforms with Alipay+ Voyager's expansive wallet partnerships, we can offer travellers a more convenient and personalized booking experience. This collaboration enables us to reach a broader audience and provide tailored travel solutions that cater to the diverse needs of today's travellers.”
About Ant International
With headquarters in Singapore and main operations across Asia, Europe, the Middle East and Latin America, Ant International is a leading global digital payment, digitisation and financial technology provider. Through collaboration across the private and public sectors, our unified techfin platform supports financial institutions and merchants of all sizes to achieve inclusive growth through a comprehensive range of cutting-edge digital payment and financial services solutions. To learn more, please visit https://www.ant-intl.com/
About Alipay+
Ant International's Alipay+ is a unified wallet gateway with cross-border payment and digitisation services that help connect global merchants to consumers. Consumers enjoy seamless payments, a broad choice of deals and the convenience of digital services using their preferred payment app/e-wallet while travelling abroad. Many small and medium-sized businesses already use Alipay+ digital tools to enhance efficiency and achieve omni-channel growth.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250701160496/en/
Contacts
Scott Lai
scott.lai@ant-intl.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom